Ganirelix
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ganirelix: From Controlled Ovarian Stimulation to Hypertrichosis
One-Sentence Summary
Ganirelix is a synthetic GnRH (Gonadotropin-releasing hormone) antagonist used internationally in assisted reproductive technology (ART) to prevent premature LH surges during controlled ovarian stimulation, though it is not currently registered in Singapore. The TxGNN model predicts it may be effective for Hypertrichosis, with a prediction score of 99.98%, however there are currently no clinical trials and no publications specifically supporting this drug-disease pairing, and the mechanistic rationale is considered weak for most hypertrichosis subtypes.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Controlled ovarian stimulation (ART) — not registered in Singapore |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on known pharmacological information, Ganirelix is a synthetic decapeptide GnRH antagonist that competitively blocks GnRH receptors in the anterior pituitary, rapidly suppressing the secretion of LH (luteinising hormone) and FSH (follicle-stimulating hormone). This in turn reduces sex steroid production from the gonads — the core mechanism underlying its use in ART protocols.
A narrow subset of hypertrichosis cases may have a hormonal component. For example, androgen-driven hirsutism associated with polycystic ovary syndrome (PCOS) involves excess LH-stimulated androgen secretion from the ovaries. In theory, a GnRH antagonist suppressing LH could reduce ovarian androgen output and thereby attenuate androgen-dependent hair follicle stimulation. This represents the sole plausible mechanistic bridge between Ganirelix and hair over-growth.
However, hypertrichosis in its broader classification is predominantly a genetic condition — arising from structural mutations (e.g., Ambras syndrome, congenital hypertrichosis lanuginosa) that are entirely independent of the hypothalamic-pituitary-gonadal (HPG) axis. The TxGNN model's high score most likely reflects a phenotypic false positive: the model recognises "hair follicle over-activity" as a shared surface feature without distinguishing genetic from hormonal aetiology. The mechanistic connection between Ganirelix and hypertrichosis is therefore rated as weak, and this prediction should be interpreted with caution.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This is a model-only prediction (L5 evidence) with zero supporting clinical trials or publications, and the dominant subtype of hypertrichosis is genetic in origin — a disease pathway for which Ganirelix has no mechanistic leverage. The high TxGNN score is best explained as a phenotypic similarity artefact at the hair follicle level rather than a true pharmacological signal.
To proceed, the following is needed:
- Clearly define the target patient population: androgen-driven hirsutism (e.g., PCOS-related) must be distinguished from genetic hypertrichosis before any further evaluation is meaningful
- Retrieve full MOA data from DrugBank (DB06785) to formally characterise the HPG axis suppression profile
- Conduct a focused literature search on GnRH antagonists (as a class) in hirsutism and hyperandrogenism to establish class-level precedent
- Review more mechanistically coherent predictions in the same candidate set: Central Precocious Puberty (rank 9, score 99.75%) and Aromatase Excess Syndrome (rank 8, score 99.80%) both involve GnRH-dependent hormonal pathways and warrant independent evaluation before hypertrichosis is revisited
- Obtain Singapore package insert warnings and contraindications to complete the safety profile required for Stage S1 evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.